Santiago Munné

Whole genome preimplantation genetic testing for transmitted and de novo mutations (PGT-WGS): assessing practicality and potential at Session 2 on Thursday 11th April

Ph.D. in Genetics from Pittsburgh University. In 1993 he developed the first Preimplantation Genetic Test for Aneuploidy (PGT-A) (1994, 1995 SART prizes) and PGT for translocations (1996, SART prize), and demonstrated that PGT-A reduces miscarriages and increases implantation rates (1998 SART prize). Santi has published >260 scientific publications, received SART and ASRM prize papers in 1994, 1995, 1998, 2005, 2015, 2016, 2020, SRBT in 2022 and the ASRM Star Award consecutively for 2011-2022.

In 2001 founded Reprogenetics with Jacques Cohen and David Sable, and as its CEO Reprogenetics became the first commercial US PGT laboratory, performing over 100K procedures. Reprogenetics was sold in 2016 to Cooper Companies (NYSE: COO).

In 2011 he co-founded with Alex Bisignano Recombine, which offered genetic carrier screening and was bought by Cooper Companies in 2016. These companies became CooperGenomics and Dr. Munné became its CSO. In 2017 he co-founded MedAnswers with CEO Alice Crisci, an infertility telehealth platform. In 2017 he joined Martin Varsavsky and Joson Horcajadas to co-found Overture Life, a company focused on automating the IVF Laboratory, which in 2023 published the first babies conceived with automated ICSI. Santi is a co-founder and president of HoMu Health Ventures, an incubator for early-stage biomedical research specialized in reproductive medicine, which has invested in SAMA, Butterfly Bio, GenEmbryomics among many other companies. He serves in several Advisory Boards of companies in reproductive medicine.

As of January 2024 he is the scientific director of Progenesis.